Al comparar la eficacia y la seguridad de alprazolam, imipraina y placebo en el tratamiento
del trastorno de pánico, se observa que ambas drogas activas muestran una superioridad …

It is just over 30 years since MAOIs were first introduced into clinical practice in the United
Kingdom. Early work suggested their usefulness in atypical states and in patients with …

The efficacy of aniidepressanl. s in treat ing panic disorder (PD) has prompted clinicians to
investigate (he role of monoamines in the pathogenesis of PD. Because amid epressLiiits …

In this short review, an attempt is made to assess the evidence implicating a disorder in
central biogenic amine neurotransmission in panic disorder. Circumstantial evidence …

Preview Patients with panic disorder and agoraphobia may seek help from their primary
care physician. Routine referral to a psychiatrist is not necessary in most cases. According to …

Although monoamine oxidase inhibitors (MAOIs) have had their clinical obituary written on
many occasions in the 33 years since they were first introduced to clinical practice they …

This paper is a brief review which deals with research findings, clinical issues, and
strategies in the pharmacotherapy of clinical depression. The author introduces …

In 1981, panic disorder was officially recognized as a separate illness and not merely a
component of generalized anxiety disorder. Panic disorder is characterized by panic attacks …

Aute anxiety is a general term encompassing a variety of symptoms that range from transient
exacerbations of background levels of anxiety to specific responses to anxiety-provoking …

Engel JA, Söderpalm B. Pharmacologic aspects of treating anxiety. Non-benzodiazepines.
The need for pharmacologic alternatives to the benzodiazepines (BZD) in the treatment of …